Ovarian Cancer Diagnostic Market Growth:
Projected Increase from $1.5 Billion in 2023 to $2.7 Billion by
20321 Amidst Current Challenges of Insufficiently Sensitive Blood
Tests for Early Detection
Aditxt, Inc. ("Aditxt") (NASDAQ: ADTX), a company dedicated to
discovering, developing, and deploying promising health
innovations, announced that its subsidiary, Pearsanta, Inc.
(“Pearsanta”) has submitted a proposal for the Clinical Trial
Translational Endpoints Research Award to the Congressionally
Directed Medical Research Programs (CDMRP) of the Department of
Defense. The proposal aims to validate a novel assay based on
Pearsanta’s proprietary Mitomic® Technology for the early detection
of ovarian cancer.
According to the World Ovarian Cancer Coalition, ovarian cancer
remains a significant health concern, with over 324,603 new cases
diagnosed worldwide in 2022. It is the 18th most common cancer
globally and the 8th most common among women, according to the
World Cancer Research Fund International. The lifetime risk for a
woman being diagnosed with ovarian cancer is approximately 1 in 87,
while the risk of dying from invasive ovarian cancer is about 1 in
130, based on information provided by the American Cancer Society.
According to the Ovarian Cancer Research Alliance, the five-year
relative survival rate for ovarian cancer stands at around 50.8%.
Despite the prevalence of this cancer, Pearsanta does not believe
that any blood tests are currently available with adequate
sensitivity for early detection of ovarian cancer, underscoring a
critical need for improved diagnostic methods.
Pearsanta’s Mitomic Technology Platform seeks to harness the
unique properties of mitochondrial DNA (mtDNA) to detect disease
through non-invasive, blood-based liquid biopsies. This platform is
designed to identify specific mutations in mtDNA indicative of
various diseases. Due to its high mutation rate and cell
persistence, Pearsanta believes mtDNA is an excellent biomarker for
early disease detection. This platform allows for the rapid and
accurate identification of disease-associated biomarkers,
significantly enhancing early diagnosis and treatment. Currently,
the program focuses on developing tests for early cancer detection,
targeting ovarian, prostate, and lung cancers, and addressing
non-cancerous conditions like endometriosis.
Pearsanta’s proposal to CDMRP focuses on validating the Mitomic
Ovarian Test (MOT), which utilizes mtDNA mutations as early
indicators of ovarian cancer. The application of mtDNA technology
to detect ovarian cancer in servicewomen could potentially also
transition to US public health funding agencies such as BARDA,
showcasing the significant potential for widespread public health
utilization. The objective is to create a reliable blood test that
can detect ovarian cancer at its earliest stages, which has the
potential to improve treatment outcomes and survival rates
significantly. In response to the CDMRP’s Clinical Trial
Translational Endpoints Research Award, the Pearsanta team has
designed a prospective cohort study collecting blood samples and
clinical information from patients undergoing surgery to diagnose
ovarian cancer. Follow-up surgical reports identify the tumor’s
presence, type, and stage. The study will enroll 100 subjects with
ovarian cancer and 200 negative controls. The control group will
include both symptomatic patients with no detected cancer and
asymptomatic patients, some of whom have a history of other
gynecologic cancers, breast cancer, or endometriosis. The study is
powered to detect significant diagnostic accuracy (AUC > 0.85)
at each stage of epithelial ovarian cancer vs. controls and
non-epithelial cancer vs. controls.
This proposal aims to validate one or more mtDNA deletions as a
test for early ovarian cancer detection. It is hypothesized that
the MOT will display acceptable diagnostic performance in detecting
all four stages of ovarian cancer, with an AUC greater than
0.85.
Chris Mitton, President of Pearsanta, stated, “Submitting this
proposal to the CDMRP is another step in our mission to
revolutionize early cancer detection. Our proprietary Mitomic
Technology aims to provide a reliable, non-invasive, and effective
blood test that can lead to earlier detection, more effective
treatments, and, ultimately, save lives. This innovation has the
potential to dramatically improve outcomes for many women,
significantly reducing the mortality rate associated with ovarian
cancer. We are focused on validating the MOT for clinical use and
supporting its launch as a Laboratory Developed Test (LDT),
fundamentally transforming ovarian cancer diagnosis and
treatment.”
Amro Albanna, Co-Founder, Chairman, and CEO of Aditxt, added,
“We believe the clinical impact of Pearsanta’s Mitomic Ovarian Test
could be profound. If we are successful in facilitating earlier
detection and more effective treatment interventions through a
simple blood test, we believe that we can significantly improve
survival rates for women with ovarian cancer, addressing a critical
unmet need in women's health. Despite the high incidence and
mortality rates, we are not aware that any blood tests are
currently available with adequate sensitivity for early ovarian
cancer detection. Our acceleration of Pearsanta’s innovations seeks
to address a critical unmet need in women's health and can
potentially save many lives.”
Aditxt currently operates two programs focused on immune health
and precision health. Following the completion of the Appili
Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) and Evofem
Biosciences, Inc. (OTCQB: EVFM) transactions, Aditxt will introduce
two additional programs dedicated to public health and women's
health. Each program is designed to function autonomously while
collectively advancing Aditxt’s mission of discovering, developing,
and deploying innovative health solutions to tackle some of the
most urgent health challenges. The closing of each of these
transactions is subject to several conditions, including but not
limited to approval of the transactions by the respective target
shareholders and Aditxt raising sufficient capital to fund its
obligations at closing. No assurance can be provided that all of
the conditions to closing will be obtained or satisfied or that
either of the transactions will ultimately close.
About Aditxt, Inc.
Aditxt, Inc.® is an innovation platform dedicated to
discovering, developing, and deploying promising innovations.
Aditxt’s ecosystem of research institutions, industry partners, and
shareholders collaboratively drives their mission to “Make
Promising Innovations Possible Together.” The innovation platform
is the cornerstone of Aditxt’s strategy, where multiple disciplines
drive disruptive growth and address significant societal
challenges. Aditxt operates a unique model that democratizes
innovation, ensures every stakeholder’s voice is heard and valued,
and empowers collective progress.
Aditxt has a diverse innovation portfolio, including Adimune™,
Inc., which is leading the charge in developing a novel class of
therapeutics for retraining the immune system to combat organ
rejection, autoimmunity, and allergies. Adivir™, Inc. focuses on
enhancing national and population health and impacting public
health globally. Pearsanta™, Inc., delivers rapid, personalized,
and high-quality lab testing accessible anytime, anywhere, led by
its CLIA-certified and CAP-accredited clinical laboratory based in
Richmond, VA.
For more information, www.aditxt.com.
Follow us on:
Linkedin: https://www.linkedin.com/company/aditxt
Facebook: https://www.facebook.com/aditxtplatform/
About Pearsanta, Inc.
Pearsanta is a commercial-stage company dedicated to
revolutionizing precision diagnostics through advanced
technologies. Leveraging its proprietary Mitomic® Technology
Platform, Pearsanta focuses on early disease detection,
significantly improving patient outcomes. The company’s diagnostic
portfolio includes tests for ovarian and prostate cancers and
endometriosis. By identifying specific mitochondrial DNA (mtDNA)
mutations, Pearsanta’s non-invasive, blood-based liquid biopsies
provide rapid and accurate disease detection. Committed to
enhancing lifelong well-being, Pearsanta addresses critical
healthcare needs with innovative solutions that empower individuals
to achieve optimal health.
Forward-Looking Statements
Certain statements in this press release constitute
“forward-looking statements” within the meaning of federal
securities laws. Forward-looking statements include statements
regarding the Company’s intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things,
the Company’s ongoing and planned product and business development;
the Company’s ability to finance and execute on its strategic
M&A initiatives; the Company’s ability obtain the necessary
funding and partner to commence clinical trials; the Company’s
intellectual property position; the Company’s ability to develop
commercial functions; expectations regarding product launch and
revenue; the Company’s results of operations, cash needs, spending,
financial condition, liquidity, prospects, growth and strategies;
the Company’s ability to raise additional capital; the industry in
which the Company operates; and the trends that may affect the
industry or the Company. Forward-looking statements are not
guarantees of future performance and actual results may differ
materially from those indicated by these forward-looking statements
as a result of various important factors, as well as market and
other conditions and those risks more fully discussed in the
section titled “Risk Factors” in the Company’s most recent Annual
Report on Form 10-K, as well as discussions of potential risks,
uncertainties, and other important factors in the Company’s other
filings with the Securities and Exchange Commission. All such
statements speak only as of the date made, and the Company
undertakes no obligation to update or revise publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law.
1
https://www.gminsights.com/industry-analysis/ovarian-cancer-diagnostic-market/market-size
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240807302870/en/
Media Relations Contact: Mary O’ Brien mobrien@aditxt.com (516)
753-9933
Aditxt (NASDAQ:ADTX)
過去 株価チャート
から 10 2024 まで 11 2024
Aditxt (NASDAQ:ADTX)
過去 株価チャート
から 11 2023 まで 11 2024
